Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone sodium phosphate
Drug ID BADD_D00625
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
Marketing Status Prescription; Discontinued
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00975
MeSH ID C004180
PubChem ID 16961
TTD Drug ID D0NA8U
NDC Product Code 67457-423; 68083-474; 67457-418; 0404-9841; 71872-7205; 68083-473; 52584-239; 70121-1452; 50090-0627; 60722-3014; 0641-6145; 70069-025; 51662-1432; 72572-122; 53225-3660; 71872-7147; 51927-0135; 71872-7021; 71872-7128; 0641-6146; 67457-484; 24208-720; 71872-7157; 70529-118; 71872-7092; 55150-304; 0404-9843; 50090-3541; 52584-421; 67457-421; 70518-3379; 51662-1391; 55150-305; 70069-024; 63323-506; 51662-1370; 49452-2473; 50090-3300; 55150-239; 70121-1451; 55150-238; 76420-077; 0395-8141; 67457-420; 71872-7171; 51662-1343; 24002-0025; 70069-022; 55154-9364; 55150-237; 67457-483; 71872-7164; 70121-1450; 67457-419; 72572-120; 71872-7091; 71872-7153; 79572-013; 52128-159; 70518-2936; 52584-420; 0641-0367; 63323-165; 50090-2313; 52584-422; 50090-4567; 70069-023; 71872-7239; 76420-185; 51927-1430; 65089-0001; 55154-8338; 0404-9842; 70518-3119; 67457-422; 0009-5027; 76045-106; 76045-109; 51662-1297; 70518-3019; 51552-0025; 76420-270; 70529-112; 38779-0071; 76045-210; 55154-5118; 70518-0532; 81565-202; 49452-2470; 57582-015; 70529-045; 63323-516; 70518-0410; 70121-1399; 70069-021; 82298-113
Synonyms dexamethasone 21-phosphate | dexamethasone phosphate | dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer | dexamethasone sodium phosphate | dexamethasonedisodium phosphate | dexamethasone phosphate disodium salt | Solu- Decadron | Spersadex | Spersadox | dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer | Decadron phosphate | dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C22H28FNa2O8P
CAS Registry Number 2392-39-4
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+ ]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cataract subcapsular06.06.01.002--Not Available
Cushingoid14.11.01.006; 05.01.01.002; 24.08.02.004; 19.07.03.001--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Erythema23.03.06.001--Not Available
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Glaucoma06.03.01.002--
Headache17.14.01.001--
Hiccups22.02.04.002; 07.01.06.009--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypokalaemic syndrome14.05.03.003--Not Available
Hypothalamo-pituitary disorder05.03.04.003--Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Large intestine perforation12.02.03.005; 07.04.06.005--
The 1th Page    1 2 3    Next   Last    Total 3 Pages